Scarica l'app Stockscreener
1.90
3.26%
0.06
Dopo l'orario di chiusura:
1.90
Precedente Chiudi:
$1.84
Aprire:
$1.85
Volume 24 ore:
1.06M
Relative Volume:
0.86
Capitalizzazione di mercato:
$262.73M
Reddito:
-
Utile/perdita netta:
$-101.70M
Rapporto P/E:
-1.0021
EPS:
-1.8961
Flusso di cassa netto:
$-84.35M
1 W Prestazione:
-6.40%
1M Prestazione:
-7.77%
6M Prestazione:
-6.86%
1 anno Prestazione:
+62.39%
Intervallo 1D:
$1.81
$1.925
Intervallo di 1 settimana:
$1.81
$2.03
Portata 52W:
$1.01
$2.66
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Nome
Alx Oncology Holdings Inc
Settore
Industria
Telefono
650-466-7125
Indirizzo
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
1.90 | 254.43M | 0 | -101.70M | -84.35M | -1.8961 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-19 | Iniziato | Wells Fargo | Overweight |
| 2026-03-06 | Ripresa | UBS | Buy |
| 2025-11-13 | Iniziato | Jefferies | Buy |
| 2025-03-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2024-03-08 | Downgrade | Stifel | Buy → Hold |
| 2023-12-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-12-22 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-06 | Iniziato | UBS | Buy |
| 2021-02-10 | Iniziato | H.C. Wainwright | Buy |
| 2020-08-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-08-11 | Iniziato | Credit Suisse | Outperform |
| 2020-08-11 | Iniziato | Jefferies | Buy |
| 2020-08-11 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Alx Oncology Holdings Inc Borsa (ALXO) Ultime notizie
ALX Oncology at Cantor healthcare conference: biomarker push takes center stage - Investing.com Canada
ALX Oncology at Wells Fargo conference: two drugs near key tests - Investing.com Canada
Alx Oncology Holdings Stock Price Forecast. Should You Buy ALXO? - StockInvest.us
ALX Oncology to Present at Upcoming Investor Conferences in September - GlobeNewswire
Three ALX Oncology presentations are set for September - Stock Titan
ALX (ALXO) Stock: Ends Up by 2.26% at $2.04 on the Day; Trading Range: the Near-Term Reference Band Stretches From $1.94 to $2.14 at the CloseMomentum Trade - vinanet.vn
ALX (ALXO) EPS and Revenue: EPS Beats Its Estimate in the Latest Session; Stock Move: Shares Close 0.96% Lower on the DayEarnings Preview - vinanet.vn
HC Wainwright Has Positive View of ALX Oncology Q3 Earnings - MarketBeat
ALX Oncology Holdings Inc (ALXO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alx oncology CEO Jason Lettmann disposes of $4,303 in shares - Investing.com
Alx oncology CEO Jason Lettmann disposes of $4,303 in shares By Investing.com - Investing.com India
Alx Oncology SVP Shelly Wong sells $1,105 of company stock - Investing.com
ALX Oncology (NASDAQ: ALXO) CEO trims stake for taxes - Stock Titan
Piper Sandler Maintains ALX Oncology(ALXO.US) With Buy Rating, Maintains Target Price $4 - Moomoo
ALXO Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers 17.9% EPS SurpriseEPS Consistency Score - vinanet.vn
ALX Oncology (ALXO) Holds Near $1.96 as Biotech Stock Consolidates Below ResistanceSingle Stock ETF - dars.gov.et
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
TCG Crossover group (NASDAQ: ALXO) reports 4.2% ALX Oncology stake in 13G/A - Stock Titan
ALXO Q2 2026 Earnings: EPS Beat of 17.92% Lifts Shares 4.15%Downward Estimate Revision - Vinanet
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
H.C. Wainwright Maintains ALX Oncology(ALXO.US) With Buy Rating, Maintains Target Price $4 - Moomoo
ALXO Q2 2026 Earnings: EPS Beats by 17.92% on Narrower Loss, But Shares Slide 6.31%Earnings Season Outlook - vinanet.vn
ALX Oncology Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
ALX Oncology Holdings Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
ALX Oncology (ALXO) Holds Steady at $2.10 as Shares Consolidate Near Key SupportSell Signal Alerts - vinanet.vn
ALX Oncology (NASDAQ:ALXO) Issues Earnings Results - MarketBeat
ALX Oncology Holdings Inc 2Q 2026: Net loss $17.97M, Diluted EPS $(0.13) — 10-Q Summary - TradingView
ALXO: Q2 2026 net loss narrowed, expenses fell, and cash reserves support operations into 2028 - TradingView
Is ALX Oncology Holdings Inc (ALXO) Turning a Corner After Q2 Ea - GuruFocus
ALX Oncology Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Investing News Network
ALX Oncology Reports Q2 2026 Net Loss of $18 Million - Quiver Quantitative
ALX Oncology reports Q2 2026 net loss of $18.0M, $153.4M cash; advances evorpacept and ALX2004 - TradingView
ALXO: Reduced net loss, robust cash position, and advancing clinical milestones drive outlook - TradingView
Clinical pipeline accelerates as ALX Oncology posts Q2 results and updates on ALX2004 study - Traders Union
ALX Oncology Reports Q2 2026 Net Loss of $18 Million | ALXO Stock News - Quiver Quantitative
ALXO Q2'26 Earnings: EPS estimate is (0.14) USD - TradingView
ALX Oncology (ALXO) Projected to Post Earnings on Tuesday - MarketBeat
ALX Oncology Holdings (ALXO) Holds Steady Near $1.94 as Biotech Sector Watches Key LevelsUnusual Call Volume - dars.gov.et
ALX Oncology (ALXO) Holds Near $1.94 as Shares Dip 0.51%Technical Analysis - vinanet.vn
ALX Oncology Holdings (ALXO) Slips Marginally as Investors Weigh Clinical Pipeline Against Cash PositionDark Pool Prints - vinanet.vn
ALXO Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Redmile Group LLC Acquires 4,699,470 Shares of ALX Oncology Holdings Inc. $ALXO - MarketBeat
ALX Oncology Holdings Inc (ALXO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ALX Oncology Holdings Inc. $ALXO Stock Position Boosted by venBio Partners LLC - MarketBeat
BlackRock (NYSE: BLK) reports 5.4% passive stake in ALX Oncology (ALXO) - Stock Titan
ALX Oncology Holdings Inc (ALXO) Cash Flow - TradingKey
2,866,256 Shares in ALX Oncology Holdings Inc. $ALXO Purchased by Orbimed Advisors LLC - MarketBeat
ALX Oncology Holdings Inc (ALXO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ALXO|ALX Oncology Holdings Inc|Price:2.030|Chg%:+0.010 - TradingKey
ALX Oncology Holdings Inc (ALXO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Alx Oncology Holdings Inc Azioni (ALXO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):